How will NICE fare in a post-Brexit world?NICE has a global reputation as a pioneering HTA – but is that influence at risk now that Share XHow will NICE fare in a post-Brexit world?https://deep-dive.pharmaphorum.com/magazine/market-access-2021/nice-post-brexit-icon/
4 ways to embed data-driven best practice in pharma HCP communicationsVirtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for Share X4 ways to embed data-driven best practice in pharma HCP communicationshttps://pharmaphorum.com/whitepapers/4-ways-to-embed-data-driven-best-practice-in-pharma-hcp-communications/
Research predicts the post-COVID landscape for HCP engagementIQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks Share XResearch predicts the post-COVID landscape for HCP engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/research-predicts-the-post-covid-landscape-for-hcp-engagement/
A year on: pandemic driven trends in HCP engagementIQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in Share XA year on: pandemic driven trends in HCP engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/a-year-on-pandemic-driven-trends-in-hcp-engagement-customer-experience/
A digital health roadmap for pharma, medical devices and insurance techCOVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for Share XA digital health roadmap for pharma, medical devices and insurance techhttps://pharmaphorum.com/whitepapers/digital-health-roadmap-pharma-medical-devices-insurance/
Deep Dive: Market AccessIt’s fair to say this is the most interesting time ever for market access. Not only has COVID Share XDeep Dive: Market Accesshttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/
Collaboration is key to advancing cell therapy researchDr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company Share XCollaboration is key to advancing cell therapy researchhttps://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/
Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovationWhen it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides Share XGlobal impact: How regulatory affairs is shaping development of cutting-edge pharma innovationhttps://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/
What Is The Best Way to Incentivise a Digital-First Sales Team?Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The Share XWhat Is The Best Way to Incentivise a Digital-First Sales Team?https://pharmaphorum.com/views-and-analysis/what-is-the-best-way-to-incentivise-a-digital-first-sales-team/
